Key result
The PreFER MVP trial is designed to randomize approximately 600 patients to evaluate whether the managed ventricular pacing algorithm reduces cardiovascular hospitalization compared to conventional pacing.
Why the study?
Does the managed ventricular pacing (MVP) algorithm reduce cardiovascular hospitalization compared to conventional programming in patients with a history of >40% ventricular pacing undergoing elective device replacement?
RCT (n=600)
Single-blind
1:1 parallel
Yes
Does the managed ventricular pacing (MVP) algorithm reduce cardiovascular hospitalization compared to conventional programming in patients with a history of >40% ventricular pacing undergoing elective device replacement?
The PreFER MVP trial is designed to evaluate whether the managed ventricular pacing algorithm reduces cardiovascular hospitalizations in patients with a history of high right ventricular pacing burden.
Answers are grounded in this paper and cite their sources.
Trial will test MVP for reducing CV hospitalization in high-burden RV pacing patients at replacement; leaves open whether algorithm improves outcomes.
AIMS: Several clinical studies have shown that, in patients with intact atrioventricular (AV) conduction, unnecessary chronic right ventricular (RV) pacing can be detrimental. The managed ventricular pacing (MVP) algorithm is designed to give preference to spontaneous AV conduction, thus minimizing RV pacing. The clinical outcomes of MVP are being studied in several ongoing trials in patients undergoing a first device implantation, but it is unknown to what extent MVP is beneficial in patients with a history of ventricular pacing. The purpose of the Prefer for Elective Replacement MVP (PreFER MVP) study is to assess the superiority of the MVP algorithm to conventional pacemaker and implantable cardioverter-defibrillator programming in terms of freedom from hospitalization for cardiovascular causes in a population of patients exposed to long periods of ventricular pacing. METHODS AND RESULTS: PreFER MVP is a prospective, 1:1 parallel, randomized (MVP ON/MVP OFF), single-blinded multi-centre trial. The study population consists of patients with more than 40% ventricular pacing documented with their previous device. Approximately, 600 patients will be randomized and followed for at least 24 months. The primary endpoint comprises cardiovascular hospitalization. CONCLUSION: The PreFER MVP trial is the first large prospective randomized clinical trial evaluating the effect of MVP in patients with a history of RV pacing.
No takes yet. Share an insight, caveat, or question.
Quesada et al. (2008) conducted an RCT in History of ventricular pacing (n=600). Managed ventricular pacing (MVP) algorithm vs. Conventional pacemaker and implantable cardioverter-defibrillator programming (MVP OFF) was evaluated on Cardiovascular hospitalization. The PreFER MVP trial is designed to randomize approximately 600 patients to evaluate whether the managed ventricular pacing algorithm reduces cardiovascular hospitalization compared to conventional pacing.
Synapse has enriched 10 related papers. Consider them for comparative context: